title: Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: an Italian, multicentre study.
abstract: OBJECTIVE
  Data on management and long-term follow-up of Helicobacter pylori-associated MALT-lymphoma in clinical practice are scanty. We evaluate the long-term efficacy of H. pylori eradication on low-grade MALT-lymphoma, and the efficacy of further therapies in refractory patients.
  
  
  METHODS
  This study enrolled patients with stages I-II(1) MALT-lymphoma and H. pylori infection. H. pylori eradication was attempted in all patients. Patients with lymphoma persistence or progression following H. pylori treatments received further lymphoma treatments. Both 5-year and disease-free survivals were calculated.
  
  
  RESULTS
  Sixty patients (stage I/II(1): 50/10) were followed up for a median time of 65 months (range 7-156). H. pylori infection was successfully eradicated in 53 (88.3%) patients following three consecutive therapeutic attempts, and lymphoma regressed in 42 (79.2%) of these patients. Sixteen patients received anti-neoplastic treatments due to either lymphoma persistence or progression, and lymphoma was cured in 14 (87.5%) cases. At follow-up, lymphoma relapsed in 13/42 (30.9%) patients within a median time of 19 months (range 3-41), and all but 1 patient were cured with further therapies. Overall, lymphoma regression was achieved in 56 patients (93.3%). The 5-year and disease-free survivals were 94.7% and 74.6%, respectively.
  
  
  CONCLUSIONS
  In clinical practice, a conservative approach with antibiotic eradication seems to be appropriate management for early-stage MALT-lymphoma, with oncologic therapy being reserved for those patients who fail to respond to H. pylori therapy.
authors.affiliation: Haematology and Gastroenterology Department, San Giacomo Hospital, Rome, Italy. alessandro.andriani1@tin.it
authors.forename: A
authors.initials: A
authors.lastname: Andriani
authors.forename: A
authors.initials: A
authors.lastname: Miedico
authors.forename: L
authors.initials: L
authors.lastname: Tedeschi
authors.forename: C
authors.initials: C
authors.lastname: Patti
authors.forename: F
authors.initials: F
authors.lastname: Di Raimondo
authors.forename: M
authors.initials: M
authors.lastname: Leone
authors.forename: L
authors.initials: L
authors.lastname: Schinocca
authors.forename: A
authors.initials: A
authors.lastname: Romanelli
authors.forename: G
authors.initials: G
authors.lastname: Bonanno
authors.forename: C
authors.initials: C
authors.lastname: Linea
authors.forename: M
authors.initials: M
authors.lastname: Giustini
authors.forename: C
authors.initials: C
authors.lastname: Hassan
authors.forename: M
authors.initials: M
authors.lastname: Cottone
authors.forename: A
authors.initials: A
authors.lastname: Zullo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D003520:Cyclophosphamide; D018572:Disease-Free Survival; D004317:Doxorubicin; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000302:isolation & purification; D006801:Humans; D007558:Italy; D053208:Kaplan-Meier Estimate; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D014750:Vincristine; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone